• 1992.9-1996.7 B.S in Biology, East China Normal University; Shanghai, China

• 1996.9-2001.7 Ph.D in Pharmacology, Shanghai Institute of Materia Medica, Chinese,Academy of Sciences, Shanghai, China

• 2001.7-2006.3 Postdoctoral research Fellow; Laboratory of Molecular Pharmacology, National Cancer Institute

• 2006.3-2008.7  Associate Professor, Division of Antitumor Pharmacology， Shanghai Institute of Materia Medica, Chinese Academy of Sciences

• 2008.7- Professor, Division of Antitumor Pharmacology， Shanghai Institute of Materia Medica, Chinese Academy of Sciences

• 2016.12- Adjunct professor, Department of Chemistry, Fudan University

• Screening and research of bioactive compounds

• Interaction between small chemicals and biomacromolecules

• Research and development of anticancer drugs

• Xu YC, Wang X, Chen Y, Chen SM, Yang XY, Sun YM, Geng MY, Ding J*, Meng LH*. Integration of Receptor Tyrosine Kinases Determines Sensitivity to PI3Ka-selective Inhibitors in Breast Cancer. Theranostics 2017; 7(4):974-986

• Li X, Tong L-J, Ding J*, Meng LH*. Systematic combination screening reveals synergism between rapamycin and sunitinib against human lung cancer. Cancer Lett. 2014；42:159-66.

• Chen SM, Guo CL, Shi JJ, Chen Y, Shen YY, Su Y, Ding J*, Meng LH*. HSP90 inhibitor AUY922 abrogates up-regulation of RTKs by mTOR inhibitor AZD8055 and potentiates its antiproliferative activity in human breast cancer. Intl J Cancer 2014; 135:2462-74.

• Wang X, Zhang X, Li BS, Zhai X, Yang Z, Ding LX, Wang H, Liang C, Zhu W, Ding J*, Meng LH*. Simultaneous targeting of PI3Kδ and a PI3Kδ-dependent MEK1/2-Erk1/2 pathway for therapy in pediatric B-cell acute lymphoblastic leukemia. Oncotarget. 2014；5:10732-44

• Chen SM, Liu JL, Wang X, Liang C, Ding J* and Meng LH*. Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of tumor.  Biochem Pharmacol 2012；83:1183-94

Research Support:

• Preclinical study on a novel PI3Kα-selective inhibitor CYH33. Science and technology commission of Shanghai Municipality; No. 14431905200; 2014.7-2017.9; Role: PI

•    Study on the mechanism of resistance to PI3K inhibitors. National Natural Sciences fund. No. 81373445; 2012.1-2015.12; Role: PI

• Discovery and mechanistic studies on molecular-targeted anticancer drugs. Innovative research group of National Natural Sciences fund. No. 81321092, 2013.1-2016.12; Role: key participants and project coordinator

• Study on the anticancer mechanism of catalytic inhibitors of mTOR. National Natural Sciences fund. 2012.1-2015.12; Role: PI

• Wuxi Appetec Life Science and Chemistry award, 2013

• 7th Innovative Award for women Scientists in Shanghai, 2012

• Meiji Biological Science award, 2011

• Sanofi-Aventis-SIBS Young Faculty Award，2010

• Second prize of the National Natural Science Award,  2009

• Servier Young Investigator in Pharmacology, 2008

• First prize of the Natural Science Award (Shanghai municipality), 2007

• First prize of Shanghai Pharmaceutical Science,2005

• AACR-Eli Lily Scholar-in-training Award in 2005

• 2005年AACR-Scholar-in-Training Award

• AACR-AstraZeneca Scholar-in-Training Award in 2004

• Cancer Research Training Award, National Cancer Institute, NIH, 2001-2006,